咪唑斯汀和依巴斯汀治疗慢性荨麻疹的药物经济学分析  

Drug economic analysis of Mizolastine and ebastine treatment of chronic urticaria

作　　者：王艳蓉[1] 江玲君 

机构地区：[1]浙江省温州医学院附属温岭医院药剂科,温州317500 [2]浙江省温州医学院仁济学院药学系,温州325035

出　　处：《海峡药学》2011年第6期258-259,共2页Strait Pharmaceutical Journal

摘　　要：目的讨论咪唑斯汀和依巴斯汀抗组胺药物治疗慢性荨麻疹所产生的经济成本进行药物经济学分析。方法 108例慢性荨麻疹患者随机分为治疗组与对照组,分别给予咪唑斯汀、依巴斯汀治疗28d,观察疗效并进行成本-效果分析。结果治疗组与对照组的有效率分别为88.0%、85.2%(P>0.5)成本-效果比分别为1.18和0.94,对照组相当于治疗组的增量成本-效果比为6.61。结论咪唑斯汀治疗慢性荨麻疹治疗效果佳,安全性高,与依巴斯汀相似。OBJECTIVE To discuss the mizolastine and ebastine antihistamine treatment of chronic urticaria by the economic costs of drug economics.METHODS 108 patients with chronic urticaria were randomly divided into treatment group and control group were given mizolastine,ebastine treatment of 28d,observe the efficacy and cost-effectiveness analysis.RESULTS The treatment group and control group were effective 88.0%,86.5%（P0.5） the cost-effectiveness ratios were 1.19 and 0.92 in the control group is equivalent to the incremental cost of the treatment group-effectiveness ratio of 16.29.CONCLUSION The treatment of chronic urticaria mizolastine treatment good,safe,and Ebastine similar.

关 键 词：慢性荨麻疹 咪唑斯汀 依巴斯汀 药物经济学分析 

分 类 号：F407.7[经济管理—产业经济]